Good day, and thank you for standing by. Welcome to the Roivant Q1 2022 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Paul Davis, Head of Communications. Please go ahead. Good morning, and thank you for joining today's call to discuss Roivant's financial results for the quarter ended June 30, 2022. I'm Paul Davis, Head of Communications at Roivant. Presenting today we have Matthew Gline, our Chief Executive Officer. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I would like to remind you that we're making certain forward-looking statements during today's presentation that reflect our current views and expectations, including those related to our financial performance and the potential attributes of our products and product candidates. We strongly encourage you to review the information that we have filed with the SEC, including the earnings release and Form 10-Q filed this morning for more information regarding these forward-looking statements and related risks and uncertainties. We'll begin with Matthew Gline, who will review key business updates across Roivant and Vants and provide a financial update. We'll end the call with the Q&A session. With that, I'll turn it over to Matthew Gline. Thank you, Paul, and good morning, everybody, and thank you for joining our first quarter earnings call. Today's call will be a little bit shorter than usual because we last got together about six weeks ago when we presented our year-end results. I'll begin on page 4, and I'll take you through some of the key highlights of the business today, and then we'll make some time for Q&A. As a reminder, we're excited about where we are at the end of our first quarter this year with obviously a number of important attributes, including the ongoing commercial launch of VTAMA, which we will spend a little bit of time on this morning. That is backed by a broad clinical stage pipeline, including multiple pivotal and registrational studies currently ongoing. Our target to clinic discovery program, including our proprietary QuEEN platform, that we are using to bolster that pipeline at the discovery stage. A number of sources of asymmetric potential upside, including our Genevant IP portfolio, and all of that supported by what continues to be a strong capital position with $2 billion in cash and cash equivalents and restricted cash, which enables us to finance and develop all of our programs across our pipeline. I'll start on page 5 with a brief update on the VTAMA launch. I'll say, first of all, I'm incredibly pleased with the very early information here. Obviously, as we've said on a number of occasions, we are principally tracking prescriptions at this time, and we feel script volume has been robust in the early days of the launch. Obviously, it is still the early days. We're only a couple months in, but we feel the script volume and the early feedback from providers has been very strong. There are a few key updates in recent weeks around this launch. The first is that our LTE data, our long-term extension study data, has been published in JAAD, and that highlights the 130-day remittive effect off therapy for patients achieving a PGA of 0 on VTAMA. That's something that we've talked about a fair amount before, and it's something we think is an important differentiating attribute of the drug. We also have noted that our Japanese partner reported positive phase 3 data for Tapinarof in atopic dermatitis, including statistically significant results in IGA and EASI, with plans to file that for approval in Japan. Finally, our own phase 3 study in atopic dermatitis is expected in the first half of next year, which would expand our market to potentially 15 million annual topical prescriptions. This is from the data, we're excited to note that we've become the number one most prescribed branded topical for psoriasis as of 8 weeks into our launch. On page 6, I'll note again from a script volume perspective, we are excited about how we are performing relative to other topical launches that we've seen in psoriasis. You can see a number of those launches in the solid lines here, and we feel proud of our early performance and think it's reflective of the enthusiasm around VTAMA. We also feel excited about the fact that we are approximately keeping pace with Opzelura, that's the dashed line on the slide, which is obviously in atopic dermatitis, a market about four times as large from a prescription perspective as psoriasis. Again, early days, but an exciting indicator for us. Just as a reminder, we really are principally focused on prescription volume at this time. You know, the quarter here is only for the really one month or about a month of launch data for VTAMA, so the revenues are not significant, but we're focused on prescription data as we work through our coverage and contracting. As we've said, it'll be about 12-18 months before we expect those contracts to be in place. On page seven, I just want to remind people of a few key attributes around VTAMA and sort of attributes that we think will support our blockbuster potential, both in psoriasis and potentially ultimately in atopic dermatitis. You know, we have the efficacy and durability that we need, and maybe most importantly, we have this off-treatment remittive benefit that we've talked about a fair amount. We have a broad target population with a label that permits use across the entire psoriasis disease spectrum, from mild to moderate to severe. We have no warnings or precautions at all, nor do we have any restrictions or notes about concomitant medications on our label. We're labeled for use on all areas of the body, and notably that includes intertriginous areas. And something we've talked a little bit less about that I'll remind everyone on this call, we have statistically significant improvement in itch as early as week 2 in our study data. On slide 8, I've put that itch data in the presentation so that we can just look at it, remind us of the data. You can see the data across the 2 studies here. One thing I'd like to call your attention to is that we saw statistically significant separation from vehicle on impact on itch as early as week 2 in our studies. You can see those P values on the slide. Notably, this comports with some of the early feedback we're getting from prescribers and patients, which is to say that overall, I would say one of the early attributes that we're hearing is that the drug is working faster than people expected, and we're obviously pleased to hear that from the field. I'll close on VTAMA on slide 9, just to update our differentiation profile versus the field for psoriasis. Obviously one of the main updates here is that ZORYVE was approved recently, and we've updated this chart accordingly. You can see we feel we have a truly differentiated profile. We are among the only topicals to have an on-label remittive benefit. We continue to be pleased with the fact that we have no duration limitations, no body surface limitations, including no limitation against intertriginous regions. We have no safety warnings or precaution section on our label. We have no label drug interactions and no contraindications as well, which is something that's differentiated versus some of our competitors. So with that, I'll move on from VTAMA, although I'm sure we'll touch on it in the Q&A section as well. I'll talk a little bit, if you jump forward to slide 11, about where we are from a clinical perspective with all of the programs backing that up. We're showing here a subset of our pipeline. We're focusing on some of the most important and latest stage programs, notably including our VTAMA study in atopic dermatitis that I mentioned before. We also have now begun our phase 3 program in brepocitinib and dermatomyositis, and we have our ongoing program in brepocitinib in lupus that I'll talk about in a moment that's going to enroll its last patient any day now. At batoclimab, there have been a number of updates that we have put out recently, including the fact that multiple of their pivotal trials are initiated in indications that we think could be blockbuster indications for batoclimab. Looking forward to sharing more about that generally as those programs progress. You can see on slide 12 some of the sort of features of our current clinical positioning, including the fact that by the end of this year, we will have 7 trials, including 4 pivotal trials ongoing, with progress across multiple fronts. I won't talk about each of the individual studies here. We expect 3 or more additional initiations of programs in 2022, notably including we've already initiated, as I mentioned, the programs in batoclimab in myasthenia gravis. We expect to be initiating a thyroid eye disease study imminently. The last thing I want to do on this call before I turn it over to Q&A is we went through the most recent addition to our pipeline, brepocitinib at Priovant last quarter at the year-end call earlier this summer. I just want to reiterate some of the features of that program because it's a program that we're very excited about in our late-stage portfolio, and because, as I mentioned before, we are expecting the final patients to enroll in our lupus study any day now, and we think that'll be an important catalyst for us next year. We wanted to continue to draw attention to that program. You know, brepocitinib overall, as a reminder, is a unique dual-targeted first-in-class TYK2 and JAK1 inhibitor, which we're developing for a variety of specialty autoimmune diseases. We think that dual inhibition of TYK2 and JAK1 is scientifically important because we think it'll potentially provide greater efficacy than agents that inhibit either one alone in inflammatory autoimmune disease where both pathways are relevant and where the interaction between the pathways is relevant. We have extremely robust. As a reminder, this program, we licensed it from Pfizer and announced it last, in the last call. We have extremely robust clinical data, statistically significant, clinically meaningful benefits in five placebo-controlled studies demonstrated to date in our oral formulation, including exposure of over a thousand subjects with a safety profile consistent with approved JAK inhibitors. We have, we think, a distinctive strategy to develop the program, including development in a series of uncrowded orphan and specialty autoimmune diseases where there's high morbidity and mortality, where there's high unmet need, and where we think the science of our drug, the dual inhibition of TYK2 and JAK1, will contribute directly to efficacy. We have two ongoing registrational programs, including a single registrational phase 3 study in dermatomyositis that we've already initiated, as well as a large global phase 2B study in lupus that's expected to complete enrollment this month, with data expected in the second half of next year. That's designed to serve as one of two registrational studies in that indication. Finally, we have strong intellectual property protection. On slide 14, I don't think I need to remind people in great detail, but you know, SLE is an important disease with obviously many patients, up to 300,000 people in the United States affected by it. And there's significant unmet need and obviously a disruptive and difficult clinical presentation. There are not very many approved therapies that work well, and those therapies are commercially successful and provide important benefit to patients, so with significant room beyond. On page 15, a reminder of a little bit of the rationale that we have for why we think this drug will be exciting in SLE. That's first of all, there is data from a number of JAK1 or TYK2 inhibitors in SLE. In both cases, we see signs of efficacy, but with significant room of improvement. You can see on this slide the placebo-adjusted response at week 24 on the left-hand side from a phase 2 study of baricitinib in SLE, and you can see a nice response there, as well as the phase 2 study on the right of deucravacitinib, a TYK2 inhibitor in SLE. Again, you can see a nice response there. There's obviously significant room across both of these for improved overall efficacy. Again, we think that we have the opportunity with brepocitinib to improve on both of them. One of the rationales for that, one of the reasons we think we may be able to do well on page sixteen is there are a number of existing indications where we have data in both brepocitinib and either deucravacitinib, baricitinib or both. You can see that data shown here. We are not currently prosecuting any of these indications for brepocitinib, but they give you a sense of just how significant our efficacy has been across multiple studies with the drug. That makes us excited for what we expect we might be able to see in this SLE study. You can see on slide 17 the design of that study. As I said, we're expecting our last patient to enroll any day now. It's a 52-week study with a couple of different dose arms. You can see all of that on page 17. With that, I'll wrap up on some of the specific updates. I'll note on the next slide 18, just we are having and we've announced our annual Roivant Investor Day will be on Wednesday, September 28, at 11:00 A.M. More details to come about that. We're excited to hear from any of you then. We're excited to share a number of key updates around the business, including R&D updates and others, at that event. I'll close and obviously the market continues to gyrate, but even with some little green shoots, just to say we are extremely privileged from a capital position perspective. If you jump forward to page 20, I'll just point out some of the key financial items for the quarter. We have R&D expense of $136 million or adjusted R&D non-GAAP, $123 million. SG&A of $149 million or adjusted non-GAAP of $88 million, for a total adjusted net loss of $354 million or an adjusted net loss of $211 million. Our cash and cash equivalents and restricted cash stayed at about $2 billion for the quarter, which we think is important for being able to support our activities. We have balance sheet debt of approximately $417 million, of which only $33 million is sort of a standard credit facility with a carrying value of $33. The remainder are milestone or fair value of royalty obligations related to VTAMA. We have 703,625,000 common shares issued and outstanding as of Friday. Finally on slide 21, I'll just remind everybody this is an incredibly catalyst-rich period for our business with obviously regular ongoing updates on VTAMA, as well as new mid- and late-stage in-licensing that's ongoing currently, and that I'm excited to provide updates on. We'll continue to provide updates on our LNP patent litigation at Genevant as we have them, and continue to provide updates on QuEEN on our greater discovery efforts, as we have them as well. In addition to that, we'll be initiating multiple pivotal programs. I've mentioned some of these on this call. We'll get top line data from a number of pivotal programs within the next 12 to call it 15, 18 months, between VTAMA and brepocitinib. We expect potential data from RVT-2001 in our phase 1/2 trial at lower risk myelodysplastic syndrome, next year. We continue to work towards data on other programs as well. It's an exciting period of execution for us. Looking forward to connecting with everybody on our Investor Day and looking forward to continue to track many of these things, including the VTAMA launch in the weeks and months to come. With that, I'll conclude my remarks for the day and I'll open the line for Q&A and hand it back to the operator. As a reminder, to ask a question, you will need to press star one one on your telephone. Please stand by while we compile the Q&A roster. Our first question comes from David Risinger with SVB Securities. Your line is now open. Great. Thank you very much, and thank you for the updates. I have a few questions. First, could you talk about the expected ramp of VTAMA going forward, particularly in the face of competitive dynamics? Second, could you discuss how you're thinking about gross to net over the next couple of years, particularly relative to street expectations and what you're seeing from the sell side? Then third, could you comment on the cash burn in the quarter and remind us about your cash runway? Thank you very much. Thanks, Dave. Thank you for all those questions. They're all good questions and I'm happy to take them, so I appreciate it. You know, I'll start with the VTAMA question, which is, you know, it's early in the launch to make long-term projections on a ramp. We are pleased with the early prescription data, and we think it sets us up well, and we're pleased with the engagement we've had with patients and physicians and with some of the early feedback we're getting on the drug. So all of that reads well. You know, you asked about competitive dynamics. The first thing I'll say, which I think is an important point that we're just gonna reiterate over and over again, is we don't view this as a competitive market versus other novel agents first and foremost. We view it as a competitive market versus corticosteroids, where there are literally millions of people on corticosteroids for psoriasis. Literally millions of prescriptions for corticosteroids and psoriasis. We think we have better efficacy and better tolerability that should allow us to take significant share from that whole category of agents, which is currently the standard of care mainline therapies. That's the first thing I'd say. As far as the competitive landscape is concerned, I think there's a new topical competitor now on the market in ZORYVE. It's a drug that has some nice attributes. We think we are differentiated meaningfully between our remittive benefit and our overall more simple safety picture without contraindications or restrictions on concomitant meds. That said, we also think more voice share and novel topicals for psoriasis is helpful. We think there will be a little bit of a rising tide effect overall. I would say, you know, given the population that we're going after, I'm excited about our ramp, and I'm not too concerned from a competitive perspective. I think as you see some new impressive systemic agents coming, I think it'll be even more important to folks like payers to have a real off-ramp, to have a real opportunity for people to stay on on topical therapy versus moving to some of these what I expect will very expensive systemic agents or new biologics. I think that'll also provide a good opportunity for us in the marketplace. Second, on gross-to-net dynamics and sell-side expectations, I guess this is a great question. It's an important topic. Just to be very clear about it, our expectation is that our gross-to-net yields will be low for the next while here. We've said 12-18 months to commercial contracts. You know, I think as far as street numbers or consensus, you know, I won't comment specifically, but I'll just say it's important for us to say over and over again, you know, we think our gross net yields are gonna be low during the period when we're getting contracts in place, and we think they'll normalize only after we have those commercial contracts in place and payers are converted from uncovered. That's a function, and we've talked about this before. It's a function of things like the new to market blocks that make it difficult until those contracts are in place. We are learning every day from the marketplace, including looking at, you know, formulary positioning for a couple people that have gone before us and watching what that looks like. We're just excited to see where those discussions shake out, and we'll provide an update on contracts when we have it. The last question on burn and runway. You know, I think we've said this before, but it's an important point. We always look to run the business with about 2 years of runway, or I should say visibility into about 2 years of runway. We have a pretty broad portfolio, so it's very easy for us to optimize, to extend our runway, to manage our runway. I'll say we continue to run the business with that in mind. We have lots of options to extend runway, including partnerships, delaying or terminating lower priority programs, et cetera, as well as monetizing stakes across the Vants portfolio, things like Datavant that you know as an independent holding that we're constantly looking for opportunities around. We are excited about that. You know, I'd say you may see some swings in our sort of working capital over the last couple of quarters or next quarter just as the Tapinarof royalty financing works its way through. I don't think that's gonna have any meaningful effect on long-term burn. Thanks, Dave. I think that covers the three questions there. Great. Thank you. Please stand by for our next question. Our next question comes from Dennis Ding with Jefferies. Your line is now open. Hi, guys. Thanks for taking the questions. Two for me. First one, can you please give some more granularity on the launch in terms of who and where it's being prescribed? You know, are you seeing it mild to moderate? And maybe talk about how penetrated are those accounts that you guys are currently in. Then secondly, perhaps on Priovant. You know, you guys mentioned that you had an AR degrader. Remind us what that is, and you know, when can we expect the next? Thank you very much. Yes. Thank you, Dennis. That's both good questions. I'll start on the VTAMA question. You know, we've seen I think we mentioned in the slides, 3,000 people write VTAMA prescriptions. We've been focused early on the sort of highest prescribing docs, the docs who who write a significant percentage of topical prescriptions and who are the general thought leaders on novel topical agents. You know, we've seen many docs have written multiple prescriptions. And obviously, there's some concentration there. Then there's a whole population of doctors, even in that high prescribing population that we're still getting out to, we're still getting our message out to. I think there's a lot of room to run there. We have not sort of focused on a specific disease severity band. Within those docs. We don't have a specific strategy as far as disease severity or subsetting the patient population. I would say we get reports in the field from a variety of different patient populations, including mild patients who didn't like being on steroids, but also including reports from severe psoriasis patients who, for example, were on the cusp of using a systemic agent and have been pleased with their VTAMA experience in ways that may forestall that for them. You know, it's been a pretty broad patient population and a lot of interest in the drug from across the spectrum. We're pleased with both the number of prescriptions and the number of unique prescribers. Your second question was around the androgen receptor degrader. You know, I think we're still looking at that program, both our data that we're sort of getting the final wisps of and our competitor data. To be honest, it's the kind of program that we're watching closely in the context of the recent drug pricing legislation. I would say the bar for that is high and we're still sort of evaluating our options there, and we'll provide an update when we've got one. I appreciate the question. Thank you, Dennis. Thanks. Please stand by for our next question. Our next question comes from Neena Bitritto-Garg with Citi. Your line is now open. Hey, guys. Thanks for taking my question. I was just wondering if you could talk a little bit more. I know, Matt, you just mentioned that you are seeing some docs write multiple prescriptions. If you could talk a little bit more about just the general prescriber behavior you're seeing. Are you seeing docs generally prescribe to maybe 1-2 patients first, see how things go with those patients, and then kind of opening up their broader, you know, population of patients? And then also any initial kind of feedback or anything you're hearing on folliculitis, that'd be great. Thanks. Yes, thanks, Neena. Well, it's a great question overall, and both parts of it are good. We don't have specific data to share right now on, you know, whether docs are kind of dribbling out or not. I would say anecdotally, we have a pretty wide variety of prescriber behaviors from true believers who are shooting out of the gate and continuing to shoot to docs who have become more and more enthusiastic about the drug as they've had positive patient experience. You know, I think I mentioned we continue to get lots of positive reports from docs and patients in the field. I would say one attribute that's coming back that we saw in our data, but I think it's been exciting to hear in the real world has been the onset of efficacy. I think patients are pleased with how fast they're seeing results. Another set of reports that we're seeing, which I mentioned, are from patients who, you know, were sort of on their last gasp as far as topicals were concerned and were sort of evaluating progression to systemic agents. I think it's been a real breath of fresh air for that patient population. We've heard positive reports from docs and patients about that from both. On folliculitis, I'll just say I think it's as we predicted. We have not heard any significant rumblings about it. It's not something that we think is meaningfully affecting the way docs use the drug or meaningfully affecting the patient experience given that it's transient and on target for the drug. Nothing new or significant around folliculitis that we think is affecting commercial behavior. Thank you, Neena. Got it. Thank you. Thanks for listening. Please stand by for our next question. Our next question comes from Louise Chen with Cantor. Your line is now open. Hi. Thanks for taking my question. I had a few for you. First one I wanted to ask about was brepocitinib and the SLE market landscape and how you think about that for your product, and also why you chose this one and dermatomyositis as the first two indications. Secondly, on the Japan Tobacco, congratulations on that news. If you could be more specific on the feedback or the read-through to your AD studies, that would be very helpful. Thank you. Last one I just wanted to ask you was, you know, broadly, what is the physician feedback on VTAMA and how they view it as an addition to the market here with one of the first topicals being approved, novel topicals in a long time? Thank you. Great. Thank you, Louise. All really good questions, and appreciate them all. So thanks for listening. You know, on the first on brepo with SLE, as you know from covering the field, is, you know, littered with lots of people who have tried lots of things. The competitive landscape is really, there's two approved biologics, with lots of unresponsive patients and many others who experience a partial response. It's a disease that has been historically stymied by a combination of agents that haven't worked as well as they could have and then just poor development, execution. So we see a huge opportunity for a novel agent. You know, we talked about this a little bit on our annual call, and maybe some of the slides there are useful to refer to, as you're looking back on it. I think there's good scientific rationale for the combination of TYK2 and JAK1 being important in lupus. You know, we've seen the recent data from baricitinib on the TYK2 side. We've seen baricitinib on the JAK1 side. We put that data in this deck. We think we have a real opportunity there. As we mentioned last time, this is a study that we're running together with Pfizer, and it's gonna be a capital efficient program for us with a readout next year. We see it as an opportunity. You know, as far as why we've chosen these indications. I'd say these are both diseases with a high morbidity and mortality with no approved oral therapies at all. As I said, in the case of lupus, the approved therapies are biologics in them. No approved oral therapies, high morbidity and mortality. Then maybe most importantly, from a scientific perspective, we're looking at diseases where we think the biology of both TYK2 and JAK1 are relevant and potentially where we're going to see some synergistic effect between TYK2 and JAK1 that will make us better than even a combination of independent JAK1 or TYK2 agents might seem to be based on their data. I'd say those are our main indications, like lupus and dermatomyositis reflect that. That's on brepocitinib. Thanks for that question. On JT, thanks, thank you for taking note of it. You know, it's obviously we're excited to see it. It's always good to see a positive readout in one of your programs, especially in an indication where you're currently running a study. I'll note that study is significantly smaller than our phase III study. To see statistically significant results in the two key endpoints there, in a smaller study and to know that they're carrying the program forward through registration is obviously all great and feels like good read-through for us. You know, ultimately, they're going to publish their data, but we're looking forward to our own data, and we think our data is going to read out before they make theirs publicly available. Yeah, I think it's a good positive read-through on our efficacy in AD. Finally, physician feedback. We've gotten a couple different versions of this question this morning, and I'm always happy to take it because I've been incredibly pleased with the quality of the physician feedback. You know, I think, look, I think docs were hungry for an effective novel topical agent. I think patients were hungry for an effective novel topical agent. I think some of what we are seeing in the physician feedback is just generally that outcome. The docs are excited to have something new to prescribe, and patients are excited to have something new and non-steroidal to go on. I think some of the feedback we're getting is frankly just specific to our agent in terms of the feedback on the onset of efficacy and being fast in terms of the feedback on you know, it's obviously early for us to be seeing the sort of quote-unquote remittive benefit. Early feedback that is consistent with that idea. So I think yeah, I think it's been a really positive experience for docs and patients so far from what we can tell and makes us excited for what's to come. Obviously, there's a lot of work to do to build that into the size of market opportunity that we think it deserves to be. We think topicals and psoriasis are going to be a really big opportunity, and we think VTAMA is going to be a really important drug, a sort of best-in-class drug in that category. Early feedback is positive. We're excited to generate more of it. Thank you. Thank you, Louise. Please stand by for our next question. The next question comes from Douglas Tsao with H.C. Wainwright. Your line is now open. Hi. Good morning. Thanks for taking the questions. Just, Matt, maybe just as a quick follow-up to Louise's question on the VTAMA readout, in Japan, just to confirm, those two studies have the same or that study had the same primary endpoint as the study that you're currently running in atopic dermatitis, correct? Yeah. I think primary and key secondary were IGA and EASI, which are also important endpoints for us. Exactly. That is correct. Yeah. I just wanted to confirm because that sort of obviously highlights that the read-through- Yep. Your study should be. Exactly. Should be very strong. Yep. just when you think about the progress and just curious in terms of the early feedback that you've been getting from payers in terms of getting contracts into place and how they're thinking about sort of prior authorizations and where they see this being put into the treatment paradigm. Because obviously, to your point, it could represent an attractive opportunity as an off-ramp for more expensive biologics. Yeah. Thanks, Doug. I appreciate that question. It's a good one. Yeah, obviously, those are all active discussions. It's hard to comment on specifics of where they are. You know, I think the point you highlighted is obviously an important point to everybody and hasn't been lost on anybody that it's important to have an off-ramp before biologics. You know, I think we've said before our view on the treatment landscape is that we should be mainstay of therapy, which is, you know, important, so not just as sort of a pre-biologics option, but really as the baseline of care. That's just sort of where we think the drug deserves to be positioned. We think obviously the factors around biologics will help us in getting the positioning we want. The second thing I'd just remind people of is remember that the main thing that insurance companies care about, that payers care about in determining coverage is demand. That, you know, obviously the scientific attributes of the product are something they look at carefully, and they have expert panels. But the way that sort of gets realized is around commercial demand. The early script volume that we're seeing here is incredibly important, we think, in ensuring that we have the kind of credible broad coverage that we want. We talked a fair amount in the approval call about our pricing strategy and about making sure that we had both a price point that would be attractive to, you know, list price sensitive payers, but also importantly, a price that offered us the opportunity to offer significant rebates to those PBMs that are rebate sensitive. I think all of those dynamics are important. We think they're gonna matter. You're absolutely right that biologics are a really big pain point for payers right now, so they're all gonna be very focused on defraying that spend over time. Just one quick follow-up. I mean, how do you envision obviously getting contracts in place for psoriasis? How long do you think it will take when you look to add the atopic dermatitis indication? Should you think that should come in place fairly quickly soon after that approval? Yeah, I think once the AD indication is approved, we should see adoption in AD relatively quickly. In terms of the specifics around payer contracting and payer dynamics, I think once we have the psoriasis payer contracts in place and once we have the AD data, we'll be able to comment more specifically on that timeline. I think it's fair to say that we expect uptake in AD to be relatively quick on approval. Okay, great. Thank you so much, Matt. Congrats on the progress. Thank you. Please stand by for our next question. Our next question comes from Corinne Jenkins with Goldman Sachs. Your line is now open. Yeah, good morning. Two for me. First, on the folliculitis, you mentioned that you're not seeing much of an impact, but is that something you're having to educate physicians on, or is that something people seem to kind of understand from the get-go? With respect to just the script-to-fill rate, what are you seeing there, and how do you think the $75 patient copay or responsibility is impacting this fill rate? Yes. Thanks, Corinne. Those are both good, important questions. Yeah, on folliculitis, look, dermatologists are very familiar with folliculitis as a condition, and that's all dermatologists are pretty familiar with folliculitis as a condition. There's not a lot of education needed to sort of explain what it is. I think it's important that they have the heads-up about it. To be honest, we're just not hearing a lot about it in the field, which I think is exactly what you'd want. It's something that I think the docs are comfortable with, but also the patient experience of it is mild, it's transient. I suspect that we would be hearing more about it if many patients were asking their doctors about it after experiencing it. I think in general, it's just not having much read-through on patient or prescriber behavior is sort of how I understand the current situation to be, based on the feedback that we do have. We're not sharing specific fill rates, but I think, you know, we're extremely pleased with the overall rate of filled prescriptions. And I think that reflects the attributes of the product, it reflects the sales and marketing strategy, and it obviously reflects the impact of the copay card program in all of its features in terms of getting patients on drug. You know, we talked a little bit about how the way that our copay card is structured is also designed to help us in the coverage process, and we're continuing to follow that as well. Great. Thank you. Thanks, Corinne. Please stand by for our next question. Our next question comes from Yaron Werber with Cowen. Your line is now open. Hi, guys. This is Brendan on for Yaron Werber. Thanks for taking the question. First off, VTAMA, I just wanted to ask about the Japanese AD study. I guess, looking at the baseline demographics there and maybe the enrollment criteria, would you say that's fairly reflective of the US study and maybe what we can expect there? Then on brepocitinib, kind of building off one of the earlier questions, can you maybe just tell us where you see the bar is for you on the phase 2 study for next year, given some of the competition? I know and you also mentioned that your drug, you think, would be potentially better than even dual administration of separate inhibitors. Could you maybe elaborate a bit on why that would be the case? Thanks so much. Perfect. So, on VTAMA, the answer is the study's criteria are similar. Patient populations are different only in the sense that the study in Japan was obviously exclusively Japanese patients. I think the read-through is positive, and then just a reminder, that study is significantly smaller. I think overall that study is smaller than either of our individual phase three studies in AD. I think that's an important part of that read-through there. And then, I think your second question was on sort of Roivant and what do we think is the bar. You know, we've talked a little bit about what the unmet need looks like there. You know, I think candidly, the bar has to be pretty high. We'd want to see superior SRI-4 to the approved therapies and then good data on secondary endpoints. I think, you know, the bar for efficacy is reasonably high for the program. It would be sort of one of the only oral agents. Obviously, there's no currently approved oral agents. We think we have a pretty good opportunity there. Thank you. Please stand by for our next question. Our next question comes from Nishant Gandhi with Truist Securities. Your line is now open. Hi, this is Alex Hong with Truist Securities. Going back to the conversations with payers on formulary position, have the discussions been challenged at all with the launch of ZORYVE and the pricing point that the competitor has chosen? Has that modified the ongoing negotiations at all with the payers that you're seeing? Then also, can you remind us, are you monitoring for how many tubes per month? That patients use for VTAMA in real world practice, and if you do, are you going to present this data to investors and at what time in the future might that be? Thanks. Yes. Thanks. Those are both good questions about the VTAMA launch, Alex. Thank you. Appreciate them. Yeah, on the Arcutis price point, I guess a couple comments. One is, we're not going to comment on active discussions with payers, and Arcutis was just approved a couple of weeks ago, so, I don't think there's a sort of real-time update on the impact anyway. I think we talked a fair amount in our approval meeting about why we were pricing where we were pricing, and Arcutis has been guiding to their pricing strategy for some time. You know, I think for us it was about threading the needle between, you know, a low enough list price to appeal to those plans that we're really focused on list price, but also a high enough list price to be able to offer the kinds of rebates to the PBMs where so much of the commercial volume lies. I think we feel good about our pricing strategy, considering everything that went into it. You know, I won't. I can't comment on Arcutis pricing strategy directly, but I feel good about ours. I also think we just have a differentiated product from ZORYVE, and I think the attributes of our product need to be considered. We have a remitting benefit that we've talked a fair amount about. You know, their label has some features that we don't, including, you know, they have drug-drug interactions listed with CYP3A4 metabolized drugs. That's not a small thing. That's like atorvastatin and simvastatin and, you know, most contraceptives are included in their drug-drug interaction profiles. I think that's something that will potentially matter in practice. I think there's various sort of differentiating features that will also impact payer conversations that will also impact where we are. You know, I think the other thing is I'd say refills in general. Maybe I'll say on the question about tubes per month, you know, we don't currently provide guidance on that. It's super early, obviously. Many of our patients have just received their first prescription. You know, that said, I think refills are good indicators of happy patients, and we're seeing already refills, some number of refills just a couple months in, which I think is a great sign. At least some patients are going to use multiple tubes, going to be happy on the drug. I think we should actually be able to track to some degree, tube utilization from watching the NRX or TRx rate. I think we're happy with that. We continue to see good engagement in the MyVTAMA program as well. You know, I think overall, it's too early to come to any long-term conclusions on the refill rate or the number of tubes. You know, I think the early data is promising to us. Thanks for taking the question and congrats on the progress. Thank you. At this time, I am showing no other questions in the queue. I would now like to turn the conference back to Matt Gline for closing remarks. Well, great. Thank you, operator. Thank you, everyone, for your questions. Thank you, everyone, for listening this morning. As I said, it was a short call because our last one was just six weeks ago. We're looking forward to getting back together in September for our Investor Day and continue to provide updates on VTAMA and on many other exciting things within our business over the months to come. Thank you, everybody, and we'll talk again soon. This concludes today's conference call. Thank you for participating. You may disconnect.